BDX Becton, Dickinson and Company Common Stock
NYSE · Health Care · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 6, 2026BDX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
BDX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
| Data ex | Desdobramento | Tipo |
|---|---|---|
| 10 de Fevereiro de 2026 | 159-for-125 | Para frente |
| 1 de Abril de 2022 | 41-for-40 | Para frente |
| 21 de Agosto de 1998 | 2-for-1 | Para frente |
| 16 de Agosto de 1996 | 2-for-1 | Para frente |
| 1 de Março de 1993 | 2-for-1 | Para frente |
| 3 de Março de 1986 | 2-for-1 | Para frente |
Sobre Becton, Dickinson and Company Common Stock Visão geral da empresa da Wikipedia
Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
BD is ranked #211 in the 2024 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2023.
History
The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. It later moved its headquarters to New Jersey.
In 2004, BD agreed to pay out US$100 million to settle allegations from competitor Retractable Technologies that it had engaged in anti-competitive behavior to prevent the distribution of Retractable's syringes, which are designed to prevent needlestick injury. The lawsuit touched off a series of legal conflicts between the companies. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”.
In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock.
In April 2017, Becton, Dickinson and Company announced it would acquire C. R. Bard. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard.
In May 2021, BD announced that it would spin off its diabetes care business (https://investors.bd.com/news-events/press-releases/detail/85/bd-announces-completion-of-embecta-corp-spinoff). The spinoff was completed on April 1, 2022, to form Embecta Corporation. Embecta Corporation is a standalone public company focused on diabetes care. The name "embecta" represents the company's commitment to people living with diabetes and its corporate heritage, with the "em-" prefix evoking empathy for people living with diabetes and the empowerment of the new company and the "bect" imbibed from Becton. Becton, Dickinson and Company entered into an agreement with Embecta Corporation to be their sole supplier of cannulas through 2032. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation's cannulas used in their products.
In July 2021, BD announced it would acquire surgical scaffold maker Tepha, after having acquired Velano Vascular earlier the same month.
In 2024, BD announced it would acquire Edwards Lifesciences' critical care unit for $4.2 billion.
Finances
For the fiscal year 2017, Becton Dickinson reported earnings of US$1.030 billion, with an annual revenue of US$12.093 billion, an increase of 10.5% over the previous fiscal cycle. Becton Dickinson's shares traded at over US$192 per share, and its market capitalization was valued at over US$63 billion in November 2018.
Business segments
Currently there are three business segments.
BD Medical
In certain places, BD Medical also offers consulting and analytics related services. BD Medical's Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.
BD Life Sciences
Business units include Biosciences and Integrated Diagnostic Solutions.
Offerings include preanalytical solutions for sample management; immunology research, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics; and differentiated reagents and assays.
In February 2026, BD Life Sciences was spun out and combined with the businesses of Waters Corporation.
BD Interventional
The company's line of plastic conical screwtop test tubes, known as 'Falcon tubes', is popular and the term is sometimes used as a generic term for such tubes.
Environmental and social track record
As of February 2010, BD was ranked 18th in the EPA Fortune 500 List of Green Power Purchasers. BD was also listed among the top 100 companies in Newsweek's 2009 Green Rankings ranking of the 500 largest American corporations based on environmental performance, policies, and reputation. BD placed third in the health care sector and 83rd overall. In addition, BD has been a component of the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the four and five consecutive years, respectively.
Pfitzer et al. (2013) identify BD's development of a needleless injection system as an example of leading businesses' role in creating shared value.
Health and safety issues
In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.
In 2020, C.R. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices.
Recalls
2007 Discardit II incident in Poland
In mid-2007, the firm's Discardit II series of syringes numbered 0607186 was withdrawn from hospitals and other medical services around Poland, about half a year after the discovery of remains of dark dust in some syringes, which were alleged to have been from this series. The newspaper Dziennik Online claimed that other series such as 06022444, 0603266, and 0607297 were also suspected of being contaminated. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.
2010 Q-Syte Luer and IV Catheter partial recall
In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the cause of the problem was manufacturing deviation and claimed that it corrected the problem. BD announced that it notified customers about the recall by letter and has been working with the U.S. Food and Drug Administration and worldwide health agencies to coordinate recall activities.
2021 IV Giving Sets
In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years.
Lawsuits
In October 2024, BD agreed to settle around 38,000 US lawsuits brought by plaintiffs who claimed they were injured by BD's hernia meshes.
In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.
Viral Orlando delivery driver incident
On September 6, 2026, in Orlando, Florida, a man identified on social media as Eric Smith, reportedly an employee of medical technology company Becton, Dickinson and Company (BD), drew widespread criticism after a confrontation with a food-delivery worker was captured on video and circulated online.
The video gained significant attention after being shared by social-media commentator Tizzyent on Instagram. During the encounter, the man was recorded making racist remarks toward the delivery worker, demanding her name. The footage subsequently went viral, generating calls on social media for BD to investigate the incident and address the alleged conduct of its employee.
Social-media users subsequently identified the man as Eric Smith and linked him to BD.
Incident recap
The incident reportedly occurred around 8:30 p.m. in Orlando, Florida, while a female delivery driver was making a food delivery. According to the driver, a man confronted her for allegedly blocking the road during her delivery, before questioning her immigration status, making remarks about "illegal immigrants," threatening to call ICE, and saying he would follow her.
The driver said she initially apologized and did not provoke the confrontation. Video of the encounter was later shared by Tizzyent on Instagram, where it went viral and drew widespread criticism.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | BDX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | 53.4média 5A ≈31.2 | ≈31.2 | · | · | |
| PEG Ratio | ≈3.2 | · | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | BDX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | 9.6%média 5A ≈12.1% | ≈12.1% | · | · | |
| Margem EBITDA (TTM) | 21.0%média 5A ≈23.6% | ≈23.6% | · | · | |
| Margem de Impostos Pré-Tributação (TTM) | 7.2%média 5A ≈9.5% | ≈9.5% | · | · | |
| Margem de Lucro Líquido (TTM) | 4.5%média 5A ≈8.7% | ≈8.7% | · | · | |
| ROA (TTM) | 1.8%média 5A ≈3.2% | ≈3.2% | · | · | |
| ROE (TTM) | 3.8%média 5A ≈7.0% | ≈7.0% | · | · | |
| ROIC | 5.3%média 5A ≈5.3% | ≈5.3% | · | · |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | BDX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido (MRQ) | 0.6média 5A ≈0.6 | ≈0.6 | · | · | |
| Índice de liquidez corrente (MRQ) | 0.9média 5A ≈1.2 | ≈1.2 | · | · | |
| Quick Ratio (Índice de Liquidez Seca) | 0.4média 5A ≈0.5 | ≈0.5 | · | · | |
| Dívida de Longo Prazo / Patrimônio Líquido (MRQ) | 0.6média 5A ≈0.6 | ≈0.6 | · | · | |
| Interest Coverage (Cobertura de Juros) | 4.2média 5A ≈5.0 | ≈5.0 | · | · |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | BDX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 8.2%média 5A ≈6.5% | ≈6.5% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 5.0%média 5A ≈4.4% | ≈4.4% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 6.3% | · | · | · | |
| EPS YoY | -0.68%média 5A ≈28.1% | ≈28.1% | · | · | |
| Net Income YoY (Lucro Líquido Ano a Ano) | -1.6%média 5A ≈24.2% | ≈24.2% | · | · | |
| EPS CAGR 3Y (CAGR de LPA 3A) | -0.34%média 5A ≈5.6% | ≈5.6% | · | · | |
| EPS CAGR 5Y (CAGR de LPA 5A) | 16.5% | · | · | · | |
| Net Income CAGR 3Y (CAGR de Lucro Líquido 3A) | -1.9%média 5A ≈3.6% | ≈3.6% | · | · | |
| Net Income CAGR 5Y (CAGR de Lucro Líquido 5A) | 13.9% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | BDX | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.4média 5A ≈0.4 | ≈0.4 | · | · | |
| Inventory Turnover (Giro de Estoque) | 3.1média 5A ≈3.4 | ≈3.4 | · | · | |
| Receivables Turnover (Giro de Contas a Receber) | 7.2média 5A ≈7.9 | ≈7.9 | · | · | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$303.3K | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Dividendos Rendimento, índice de pagamento, histórico de dividendos, CAGR de 5 anos
| Data ex | Valor | Moeda | Rendimento |
|---|---|---|---|
| Set 9, 2026 | $1,05 | USD | ≈2.2% |
| Jun 9, 2026 | $1,05 | USD | ≈2.5% |
| Mar 10, 2026 | $1,05 | USD | ≈2.1% |
| Dez 8, 2025 | $0,83 | USD | ≈2.2% |
| Set 8, 2025 | $0,82 | USD | ≈2.2% |
| Jun 9, 2025 | $0,82 | USD | ≈2.4% |
| Mar 10, 2025 | $0,82 | USD | ≈1.7% |
| Dez 9, 2024 | $0,82 | USD | ≈1.7% |
| Set 9, 2024 | $0,75 | USD | ≈1.6% |
| Jun 10, 2024 | $0,75 | USD | ≈1.6% |
| Mar 7, 2024 | $0,75 | USD | ≈1.6% |
| Dez 7, 2023 | $0,75 | USD | ≈1.6% |
| Set 7, 2023 | $0,72 | USD | ≈1.4% |
| Jun 8, 2023 | $0,72 | USD | ≈1.4% |
| Mar 9, 2023 | $0,72 | USD | ≈1.5% |
| Dez 8, 2022 | $0,72 | USD | ≈1.4% |
| Set 8, 2022 | $0,68 | USD | ≈1.3% |
| Jun 8, 2022 | $0,68 | USD | ≈1.3% |
| Mar 9, 2022 | $0,67 | USD | ≈1.3% |
| Dez 9, 2021 | $0,67 | USD | ≈1.4% |
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | $3.23 | $3.17 | 1.8% | |
| 31 de Março de 2026 | $2.90 | $2.80 | 3.5% | |
| 31 de Dezembro de 2025 | $2.91 | $2.84 | 2.4% | |
| 30 de Setembro de 2025 | $3.96 | $3.96 | -0.05% | |
| 30 de Junho de 2025 | $3.68 | $3.44 | 7.1% | |
| 31 de Março de 2025 | $3.35 | $3.31 | 1.1% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | |
| Cost of Revenue | $11.91B | $11.05B | $11.20B | $10.39B | $10.50B | $9.28B | $9.00B | $8.71B | $6.13B | $6.49B | $5.59B | $4.14B | |
| Gross Profit | · | · | · | · | · | $7.58B | $8.29B | $7.27B | $5.94B | $5.99B | $4.70B | $4.30B | |
| R&D Expense | $1.26B | $1.19B | $1.24B | $1.26B | $1.28B | $1.04B | $1.06B | $1.00B | $770M | $828M | $632M | $550M | |
| SG&A Expense | $5.28B | $4.86B | $4.72B | $4.71B | $4.72B | $4.18B | $4.33B | $4.02B | $2.91B | $3.00B | $2.56B | $2.15B | |
| Operating Expenses | $19.26B | $17.78B | $17.26B | $16.59B | $16.88B | $15.16B | $15.53B | $14.47B | $10.57B | $11.05B | $9.21B | $6.84B | |
| Operating Income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B | $912M | $1.76B | $1.51B | $1.52B | $1.43B | $1.07B | $1.61B | |
| Interest Expense | $613M | $528M | $452M | $398M | $469M | $528M | $639M | $706M | $521M | $388M | $371M | $135M | |
| Interest Income | $38M | $163M | $49M | $16M | $9M | $7M | $12M | $65M | $76M | $21M | $15M | $46M | |
| Other Non-op | $-123M | $-28M | $-46M | $-117M | $-99M | $23M | $43M | $305M | $-101M | $11M | $21M | $5M | |
| Pretax Income | $1.88B | $2.00B | $1.66B | $1.78B | $1.69B | $414M | $1.18B | $1.17B | $976M | $1.07B | $739M | $1.52B | |
| Income Tax | $203M | $300M | $132M | $148M | $88M | $62M | $-57M | $862M | $-124M | $97M | $44M | $337M | |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.10B | $976M | $695M | $1.19B | |
| EPS (Basic) | $5.83 | $5.88 | $4.97 | $5.93 | $6.92 | $2.75 | $4.01 | $0.62 | $4.70 | $4.59 | $3.43 | $6.13 | |
| EPS (Diluted) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 | $3.35 | $5.99 | |
| Shares (Basic) | 287,648,000 | 289,763,000 | 286,282,000 | 285,005,000 | 289,288,000 | 278,971,000 | 269,943,000 | 258,354,000 | 218,943,000 | 212,702,000 | 202,537,000 | 193,299,000 | |
| Shares (Diluted) | 288,509,000 | 291,009,000 | 288,392,000 | 287,364,000 | 292,089,000 | 282,402,000 | 274,775,000 | 264,621,000 | 223,588,000 | 217,536,000 | 207,509,000 | 197,709,000 | |
| EBITDA | $5.04B | $4.68B | $4.40B | $4.51B | $5.07B | $3.64B | $4.01B | $3.48B | $2.57B | $2.54B | $1.97B | $2.17B |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $567M | $1.72B | $1.42B | $1.01B | $2.28B | $2.83B | $536M | $1.14B | $14.18B | $1.54B | $1.42B | $1.86B | |
| Receivables | $2.40B | $3.03B | $2.53B | $2.19B | $2.35B | $2.40B | $2.35B | $2.32B | $1.74B | $1.62B | $1.62B | $1.19B | |
| Inventory | $3.15B | $3.84B | $3.27B | $3.22B | $2.74B | $2.74B | $2.58B | $2.45B | $1.82B | $1.72B | $1.96B | $1.50B | |
| Other Current Assets | $1.38B | $1.29B | $1.38B | $1.56B | $1.05B | $891M | $1.12B | $1.25B | $871M | $480M | $563M | $698M | |
| Current Assets | $9.26B | $10.47B | $8.68B | $8.14B | $8.84B | $8.97B | $6.66B | $7.41B | $18.63B | $6.37B | $5.66B | $6.13B | |
| PP&E (Net) | $6.38B | $6.82B | $6.56B | $6.01B | $6.00B | $5.92B | $5.66B | $5.38B | $4.64B | $3.90B | $4.06B | $3.60B | |
| PP&E (Gross) | $13.66B | $14.38B | $13.58B | $12.41B | $12.09B | $11.92B | $11.13B | $10.48B | $9.39B | $8.42B | $8.28B | $7.76B | |
| Accum. Depreciation | $7.27B | $7.56B | $7.02B | $6.40B | $6.09B | $6.00B | $5.47B | $5.11B | $4.75B | $4.52B | $4.22B | $4.16B | |
| Goodwill | $25.96B | $26.46B | $24.52B | $24.62B | $23.89B | $23.60B | $23.38B | $23.60B | $7.56B | $7.42B | $7.54B | $1.09B | |
| Intangibles | $9.23B | $10.87B | $10.90B | $12.26B | $12.73B | $13.77B | · | · | · | · | · | · | |
| Other Non-current Assets | $2.38B | $2.62B | $2.08B | $1.85B | $1.95B | $1.69B | $1.09B | $1.08B | $1.01B | $824M | $717M | $488M | |
| Total Assets | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.77B | $53.90B | $37.73B | $25.59B | $26.48B | $12.38B | |
| Accounts Payable | $6.11B | $1.90B | $1.64B | $1.70B | $1.74B | $1.35B | $1.09B | $1.11B | $797M | $665M | $631M | $401M | |
| Accrued Liabilities | $3.10B | $3.48B | $2.60B | $2.60B | $2.87B | $2.64B | $2.13B | $2.25B | $1.39B | $1.57B | $1.62B | $1.05B | |
| Current Liabilities | $8.31B | $8.96B | $6.64B | $7.81B | $6.63B | $5.84B | $5.66B | $7.22B | $3.34B | $4.40B | $4.38B | $2.23B | |
| Capital Leases | $704M | $667M | $414M | $384M | $344M | $336M | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | $1.95B | $130M | |
| Other Non-current Liabilities | $2.63B | $3.56B | $4.58B | $5.05B | $5.21B | $5.75B | $5.68B | $5.74B | $1.61B | $1.68B | $2.43B | $383M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | $12.12B | $3.77B | |
| Total Debt | $17.62B | $17.94B | $14.74B | $13.89B | $17.11B | $17.22B | $18.08B | $18.89B | $18.67B | $10.55B | $12.12B | $3.77B | |
| Common Stock | $371M | $371M | $371M | $365M | $365M | $365M | $347M | $347M | $347M | $333M | $333M | $333M | |
| Retained Earnings | $16.62B | $16.14B | $15.54B | $15.16B | $13.83B | $12.79B | $12.91B | $12.60B | $13.11B | $12.73B | $12.31B | $12.11B | |
| Treasury Stock | $9.81B | $8.81B | $8.30B | $8.33B | $7.72B | $6.14B | $6.19B | $6.24B | $8.43B | $8.21B | $8.24B | $8.60B | |
| AOCI | $-1.90B | $-1.73B | $-1.55B | $-1.49B | $-2.09B | $-2.55B | $-2.28B | $-1.91B | $-1.72B | $-1.93B | $-1.74B | $-1.00B | |
| Stockholders' Equity | $25.39B | $25.89B | $25.80B | $25.28B | $23.68B | $23.77B | $21.08B | $20.99B | $12.95B | $7.63B | $7.16B | $5.05B | |
| Liabilities + Equity | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.77B | $53.90B | $37.73B | $25.59B | $26.48B | $12.45B |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.46B | $2.29B | $2.29B | $2.23B | $2.23B | $2.12B | $2.25B | $1.98B | $1.09B | $1.11B | $891M | $562M | |
| Stock-based Comp | $258M | $247M | $259M | $233M | $229M | $236M | $261M | $322M | $174M | $196M | $166M | $113M | |
| Deferred Tax | $-474M | $-211M | $-622M | $-129M | $-280M | $-285M | $-633M | $-262M | $-74M | $-519M | $-274M | $-94M | |
| Amort. of Intangibles | $1.59B | $1.47B | $1.47B | $1.43B | $1.40B | $1.38B | $1.50B | $1.25B | $553M | $552M | $346M | $84M | |
| Restructuring | $275M | $387M | $239M | $123M | $44M | $84M | · | · | $85M | $526M | $271M | · | |
| Other Non-cash | $-494M | $-183M | $-419M | $-1.64B | $333M | $553M | $216M | $516M | $262M | $792M | $252M | $-20M | |
| Operating Cash Flow | $3.43B | $3.84B | $2.99B | $2.47B | $4.13B | $2.94B | $3.33B | $2.87B | $2.55B | $2.56B | $1.73B | $1.75B | |
| CapEx | $760M | $725M | $874M | $973M | $1.19B | $769M | $957M | $895M | $727M | $693M | $596M | $592M | |
| Investing Cash Flow | $-818M | $-5.51B | $-716M | · | $-1.88B | $-1.23B | $-741M | $-15.73B | $-883M | $-669M | $-8.32B | $-948M | |
| Debt Issued | $0 | $4.52B | $1.66B | $497M | $4.87B | $3.39B | $2.22B | $5.09B | $11.46B | $0 | $6.16B | $0 | |
| Net Debt Issued | $-1.79B | $3.38B | $-493M | $-308M | $-243M | $-1.27B | $-2.52B | $1.09B | $7.48B | $-752M | $6.16B | · | |
| Stock Repurchased | $1.00B | $500M | $0 | $500M | $1.75B | $0 | $0 | $0 | $220M | $0 | $0 | $400M | |
| Net Stock Activity | $-1.00B | $-500M | $0 | $-500M | $-1.75B | · | $0 | $0 | $-220M | $0 | $0 | $-400M | |
| Dividends Paid | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984M | $927M | $677M | $562M | $485M | $421M | |
| Financing Cash Flow | $-3.62B | $2.09B | $-1.96B | · | $-3.31B | $22M | $-3.22B | $-58M | $10.98B | $-1.76B | $6.19B | $-807M | |
| Net Change in Cash | $-1.00B | $375M | $322M | $-1.23B | $-525M | $2.33B | $-646M | $-12.94B | $12.64B | $117M | $-436M | $-29M | |
| Taxes Paid | $599M | $653M | $629M | $532M | $671M | $523M | $536M | $235M | $265M | $218M | $240M | $330M | |
| Free Cash Flow | $2.67B | $3.12B | $2.12B | $1.50B | $3.42B | $2.73B | $2.37B | $1.97B | $1.82B | $1.87B | $1.13B | $1.15B | |
| Levered FCF | $2.12B | $2.67B | $1.70B | $1.13B | $2.98B | $2.26B | $1.70B | $1.78B | $1.24B | $1.51B | $785M | $1.05B |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 44.3% | 47.9% | 45.4% | 49.1% | 48.0% | 45.7% | · | |
| Operating Margin | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% | 8.7% | 10.2% | 9.4% | 12.2% | 11.5% | 10.4% | 19.0% | |
| Net Margin | 7.7% | 8.5% | 7.7% | 9.4% | 10.3% | 5.1% | 7.1% | 1.9% | 9.1% | 7.8% | 6.8% | 14.0% | |
| Pretax Margin | 8.6% | 9.9% | 8.6% | 9.4% | 11.1% | 5.8% | 6.8% | 7.3% | 8.1% | 8.6% | 7.2% | 18.0% | |
| EBITDA Margin | 23.1% | 23.2% | 22.7% | 23.9% | 25.1% | 21.2% | 23.2% | 21.7% | 21.2% | 20.4% | 19.1% | 25.7% | |
| ROA | 3.0% | 3.1% | 2.8% | 3.3% | 3.9% | 1.7% | 2.3% | 0.68% | 3.5% | 3.8% | 3.5% | 9.6% | |
| ROE | 6.5% | 6.6% | 5.8% | 7.3% | 8.8% | 3.9% | 5.9% | 1.8% | 10.7% | 13.2% | 11.4% | 23.5% | |
| ROIC | 5.3% | 4.7% | 4.8% | 5.3% | 6.4% | 3.2% | 4.7% | 1.0% | 5.3% | 7.1% | 5.2% | 14.2% |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 1.2 | 1.3 | 1.0 | 1.3 | 1.5 | 1.2 | 1.0 | 5.6 | 1.4 | 1.4 | 2.7 | |
| Quick Ratio | 0.4 | 0.5 | 0.6 | 0.4 | 0.7 | 0.9 | 0.5 | 0.5 | 4.8 | 0.7 | 0.7 | 1.4 | |
| Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 | 0.7 | 0.9 | 0.9 | 1.4 | 1.4 | 1.7 | 0.7 | |
| LT Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 | 0.7 | 0.9 | 0.9 | 1.4 | 1.4 | 1.6 | 0.7 | |
| Interest Coverage | 4.2 | 4.5 | 4.7 | 5.7 | 6.0 | 2.8 | 2.8 | 2.1 | 2.8 | 3.7 | 2.9 | 11.9 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.7 | |
| Inventory Turnover | 3.1 | 3.1 | 3.4 | 3.5 | 3.9 | 3.6 | 3.6 | 4.1 | 3.5 | 3.5 | 3.2 | 2.9 | |
| Receivables Turnover | 7.2 | 7.2 | 8.2 | 8.3 | 8.3 | 7.2 | 7.4 | 7.9 | 7.2 | 7.7 | 7.3 | 7.0 |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $75.70 | $69.34 | $67.17 | $65.67 | $69.32 | $60.61 | $62.92 | $60.40 | $54.09 | $57.38 | $49.55 | $42.72 | |
| Cash Flow / Share | $11.89 | $13.21 | $10.37 | $8.60 | $15.91 | $12.53 | $12.12 | $10.83 | $11.40 | $11.76 | $8.34 | $8.83 | |
| Dividend Paid / Share | $4.16 | $3.80 | $3.64 | $3.48 | $3.32 | $3.16 | $3.08 | $3.00 | $2.92 | $2.64 | $2.40 | $2.18 | |
| EPS (TTM) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 | $3.35 | $5.99 |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.2% | 4.2% | 2.7% | -1.4% | 19.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.0% | 1.8% | 6.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -0.68% | 18.6% | -16.0% | -14.2% | 152.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -0.34% | -5.1% | 22.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 16.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.6% | 14.9% | -16.6% | -15.0% | 139.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -1.9% | -6.6% | 19.3% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 13.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.1% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | |
| Net Income TTM | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.10B | $976M | $695M | $1.19B | |
| P/E | 25.3 | 32.3 | 41.1 | 29.8 | 27.5 | 65.9 | 49.2 | 333.6 | 32.7 | 30.7 | 30.4 | 14.6 | |
| Earnings Yield | 4.0% | 3.1% | 2.4% | 3.4% | 3.6% | 1.5% | 2.0% | 0.30% | 3.1% | 3.3% | 3.3% | 6.9% | |
| Payout Ratio | 71.3% | 64.5% | 75.1% | 60.8% | 50.1% | 117.4% | 79.8% | 298.1% | 61.6% | 57.6% | 69.8% | 35.5% | |
| Annual Payout | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984M | $927M | $677M | $562M | $485M | $421M |
Demonstração de Resultados
| Métrica | Tendência | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.98B | $4.71B | $5.25B | $5.89B | $4.73B | $4.48B | $5.17B | $5.44B | $4.99B | $5.04B | $4.71B | $5.09B | $4.88B | $4.82B | $4.59B | $4.76B | |
| Cost of Revenue | $2.67B | $2.56B | $2.84B | $3.09B | $2.49B | $2.62B | $2.93B | $2.95B | $2.68B | $2.74B | $2.68B | $3.38B | $2.78B | $2.59B | $2.45B | $2.68B | |
| R&D Expense | $258M | $249M | $306M | $323M | $230M | $232M | $343M | $302M | $299M | $299M | $290M | $281M | $306M | $337M | $313M | $300M | |
| SG&A Expense | $1.26B | $1.21B | $1.39B | $1.37B | $1.16B | $1.12B | $1.32B | $1.25B | $1.20B | $1.19B | $1.21B | $1.14B | $1.19B | $1.21B | $1.19B | $1.18B | |
| Operating Expenses | $4.32B | $4.62B | $4.70B | $5.19B | $3.99B | $4.10B | $4.71B | $4.81B | $4.39B | $4.31B | $4.27B | $4.74B | $4.33B | $4.19B | $4.00B | $4.27B | |
| Operating Income | $663M | $93M | $552M | $698M | $739M | $383M | $453M | $622M | $602M | $734M | $439M | $349M | $549M | $628M | $585M | $489M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $125M | $111M | $113M | $119M | $118M | $102M | $104M | |
| Interest Income | $4M | $9M | $4M | $5M | $4M | $5M | $23M | $55M | $48M | $26M | $34M | $9M | $24M | $10M | $6M | $7M | |
| Other Non-op | $19M | $86M | $-10M | $-36M | $-22M | $-36M | $-16M | $-9M | $-13M | $-2M | $-4M | $-63M | $17M | $8M | $-8M | $-73M | |
| Pretax Income | $554M | $39M | $393M | $509M | $569M | $201M | $306M | $513M | $500M | $633M | $359M | $181M | $471M | $529M | $481M | $320M | |
| Income Tax | $102M | $76M | $11M | $16M | $118M | $43M | $3M | $114M | $13M | $96M | $77M | $28M | $64M | $68M | $-28M | $33M | |
| Net Income | $377M | $-311M | $382M | $493M | $574M | $308M | $303M | $400M | $487M | $537M | $281M | $108M | $407M | $460M | $509M | $288M | |
| EPS (Basic) | $1.37 | $-1.11 | $1.34 | $1.71 | $2.00 | $1.07 | $1.05 | $1.38 | $1.68 | $1.85 | $0.97 | $0.35 | $1.37 | $1.54 | $1.71 | $0.94 | |
| EPS (Diluted) | $1.37 | $-1.11 | $1.34 | $1.71 | $2.00 | $1.07 | $1.04 | $1.37 | $1.68 | $1.85 | $0.96 | $0.35 | $1.36 | $1.53 | $1.70 | $0.92 | |
| Shares (Basic) | 274,788,000 | 280,640,000 | 285,582,000 | · | 287,170,000 | 287,293,000 | 289,505,000 | · | 289,562,000 | 289,518,000 | 290,113,000 | · | 286,317,000 | 284,292,000 | 283,887,000 | · | |
| Shares (Diluted) | 275,158,000 | 280,640,000 | 285,845,000 | · | 287,223,000 | 287,737,000 | 290,389,000 | · | 290,253,000 | 290,344,000 | 291,398,000 | · | 287,944,000 | 285,645,000 | 285,340,000 | · | |
| EBITDA | $1.23B | $656M | $1.17B | · | $882M | $546M | $1.06B | · | $602M | $734M | $1.00B | · | $549M | $628M | $1.15B | · |
Balanço Patrimonial
| Métrica | Tendência | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $708M | $813M | $740M | $641M | $735M | $667M | $711M | $1.72B | $4.46B | $2.35B | $1.18B | · | $923M | $1.98B | $612M | · | |
| Receivables | $2.36B | $2.21B | $2.51B | $2.99B | $2.94B | $3.03B | $2.64B | $3.03B | $2.60B | $2.56B | $2.27B | · | $2.41B | $2.41B | $2.28B | · | |
| Inventory | $3.32B | $3.36B | $4.08B | $3.89B | $3.95B | $3.72B | $3.86B | $3.84B | $3.25B | $3.23B | $3.30B | · | $3.59B | $3.66B | $3.60B | · | |
| Other Current Assets | $1.59B | $1.43B | $1.56B | $1.51B | $1.28B | $1.15B | $1.33B | $1.29B | $1.02B | $1.33B | $1.35B | · | $1.28B | $1.44B | $1.54B | · | |
| Current Assets | $8.14B | $8.01B | $9.19B | $9.26B | $9.00B | $8.67B | $8.66B | $10.47B | $12.21B | $10.34B | $8.16B | · | $8.59B | $9.59B | $8.18B | · | |
| PP&E (Net) | $6.08B | $6.08B | $6.97B | $7.00B | $6.82B | $6.65B | $6.60B | $6.82B | $6.52B | $6.59B | $6.65B | · | $6.47B | $6.36B | $6.25B | · | |
| PP&E (Gross) | $13.60B | $13.55B | $15.24B | $15.11B | $14.85B | $14.41B | $14.16B | $14.38B | $13.92B | $13.93B | $13.90B | · | $13.47B | $13.20B | $12.93B | · | |
| Accum. Depreciation | $7.52B | $7.47B | $8.27B | $8.12B | $8.04B | $7.76B | $7.55B | $7.56B | $7.40B | $7.33B | $7.25B | · | $7.00B | $6.85B | $6.68B | · | |
| Goodwill | $25.94B | $25.95B | $26.62B | $26.61B | $26.60B | $26.44B | $26.33B | $26.46B | $24.55B | $24.57B | $24.60B | $24.52B | $24.58B | $24.78B | $24.76B | $24.62B | |
| Intangibles | $8.02B | $8.35B | $9.01B | $9.39B | $9.77B | $10.12B | $10.47B | $10.87B | $9.86B | $10.21B | $10.57B | · | $11.27B | $11.63B | $11.94B | · | |
| Other Non-current Assets | $2.55B | $2.43B | $3.04B | $3.06B | $2.70B | $2.58B | $2.59B | $2.62B | $2.40B | $2.40B | $2.26B | · | $2.06B | $1.99B | $1.96B | · | |
| Total Assets | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B | $55.58B | $54.16B | $52.27B | · | $53.02B | $54.39B | $53.13B | · | |
| Accounts Payable | $6.11B | $5.93B | $6.14B | $1.97B | $6.35B | $6.09B | $6.35B | $1.90B | $5.41B | $5.31B | $5.52B | · | $5.02B | $5.09B | $5.44B | · | |
| Accrued Liabilities | · | · | · | $3.10B | · | · | · | $3.48B | · | · | · | · | · | · | · | · | |
| Current Liabilities | $9.40B | $8.51B | $8.76B | $8.31B | $8.16B | $7.69B | $7.66B | $8.96B | $6.61B | $7.33B | $7.54B | · | $6.88B | $7.30B | $7.62B | · | |
| Capital Leases | · | · | · | $704M | · | · | · | $667M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $2.39B | $2.46B | $2.81B | $2.93B | $2.83B | $3.00B | $3.42B | $3.56B | $4.07B | $4.30B | $4.41B | · | $4.37B | $4.47B | $4.86B | · | |
| Total Debt | $13.51B | $14.71B | $16.92B | · | $17.53B | $17.67B | $17.44B | · | $18.13B | $15.99B | $14.09B | · | $14.93B | $16.01B | $14.27B | · | |
| Common Stock | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | · | $371M | $365M | $365M | · | |
| Retained Earnings | $17.51B | $17.39B | $16.70B | $16.62B | $16.43B | $16.15B | $16.14B | $16.14B | $16.02B | $15.80B | $15.54B | · | $15.69B | $15.56B | $15.38B | · | |
| Treasury Stock | $12.06B | $11.66B | $10.06B | $9.81B | $9.56B | $9.56B | $9.43B | $8.81B | $8.81B | $8.81B | $8.83B | · | $8.32B | $8.33B | $8.33B | · | |
| AOCI | $-1.65B | $-1.76B | $-1.86B | $-1.90B | $-1.81B | $-1.72B | $-1.68B | $-1.73B | $-1.58B | $-1.53B | $-1.51B | · | $-1.51B | $-1.57B | $-1.56B | $-1.49B | |
| Stockholders' Equity | $24.42B | $24.13B | $25.28B | $25.39B | $25.47B | $25.24B | $25.20B | $25.89B | $25.87B | $25.65B | $25.33B | · | $25.94B | $25.69B | $25.47B | · | |
| Liabilities + Equity | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B | $55.58B | $54.16B | $52.27B | · | $53.02B | $54.39B | $53.13B | · |
Fluxo de Caixa
| Métrica | Tendência | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $564M | $563M | $614M | $629M | $575M | $567M | $607M | $586M | $568M | $571M | $561M | $587M | $571M | $563M | $567M | $581M | |
| Stock-based Comp | $55M | $58M | $91M | $55M | $54M | $59M | $90M | $51M | $53M | $60M | $83M | $58M | $56M | $56M | $89M | $49M | |
| Amort. of Intangibles | $365M | $380M | $397M | $398M | $388M | $387M | $395M | $375M | $362M | $366M | $365M | $367M | $367M | $366M | $365M | $366M | |
| Restructuring | $48M | $482M | $75M | $88M | $58M | $63M | $66M | $125M | $95M | $98M | $69M | $119M | $61M | $33M | $26M | $51M | |
| Other Non-cash | · | · | $-845M | · | · | · | $-677M | · | · | · | $82M | · | · | · | $-1.43B | · | |
| Operating Cash Flow | $776M | $671M | $657M | $1.35B | $1.22B | $164M | $693M | $1.18B | $1.30B | $514M | $855M | $1.32B | $1.08B | $185M | $399M | $973M | |
| CapEx | $143M | $125M | $108M | $352M | $174M | $129M | $105M | $296M | $179M | $134M | $116M | $294M | $191M | $181M | $208M | $315M | |
| Investing Cash Flow | · | · | $-183M | $-494M | $-336M | $-192M | $204M | $-3.94B | $-288M | $-1.06B | $-233M | $137M | $-329M | $-233M | $-291M | · | |
| Net Debt Issued | $-2.00B | $-2.00B | $0 | · | · | · | $-875M | · | · | · | $0 | · | · | · | $-528M | · | |
| Stock Repurchased | $0 | $2.00B | $250M | $250M | $0 | $0 | $750M | $0 | $0 | $0 | $500M | $0 | $0 | $0 | $0 | $500M | |
| Net Stock Activity | · | · | $-250M | · | · | · | $-750M | · | · | · | $-500M | · | · | · | · | · | |
| Dividends Paid | $286M | $290M | $299M | $297M | $299M | $298M | $302M | $275M | $275M | $275M | $275M | $265M | $286M | $282M | $281M | $270M | |
| Financing Cash Flow | · | · | $-302M | $-809M | $-841M | $-39M | $-1.93B | $124M | $1.12B | $1.71B | $-862M | $-997M | $-1.79B | $1.37B | $-534M | · | |
| Net Change in Cash | $-152M | $64M | $174M | $53M | $51M | $-66M | $-1.04B | $-2.63B | $2.09B | $1.16B | $-247M | $456M | $-1.04B | $1.32B | $-415M | $-1.60B | |
| Free Cash Flow | · | · | $549M | · | · | · | $588M | · | · | · | $739M | · | · | · | $191M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | $652M | · | · | · | $83M | · |
Lucratividade
| Métrica | Tendência | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.3% | 2.0% | 10.5% | · | 16.0% | 10.4% | 8.8% | · | 12.1% | 14.5% | 9.3% | · | 11.2% | 13.0% | 12.8% | · | |
| Net Margin | 7.6% | -6.6% | 7.3% | · | 10.4% | 5.8% | 5.9% | · | 9.8% | 10.6% | 6.0% | · | 8.3% | 9.5% | 11.1% | · | |
| Pretax Margin | 11.1% | 0.83% | 7.5% | · | 12.8% | 6.9% | 5.9% | · | 10.0% | 12.6% | 7.6% | · | 9.7% | 11.0% | 10.5% | · | |
| EBITDA Margin | 24.6% | 13.9% | 22.2% | · | 16.0% | 10.4% | 20.5% | · | 12.1% | 14.5% | 21.2% | · | 11.2% | 13.0% | 25.1% | · | |
| ROA | 0.71% | -0.59% | 0.70% | · | 1.0% | 0.57% | 0.57% | · | 0.90% | 0.99% | 0.53% | · | 0.77% | 0.84% | 0.96% | · | |
| ROE | 1.5% | -1.3% | 1.5% | · | 2.2% | 1.2% | 1.2% | · | 1.9% | 2.1% | 1.1% | · | 1.6% | 1.8% | 2.1% | · | |
| ROIC | 1.4% | -0.23% | 1.3% | · | 1.7% | 1.1% | 1.1% | · | 1.3% | 1.5% | 0.87% | · | 1.2% | 1.3% | 1.6% | · |
Liquidez e Solvência
| Métrica | Tendência | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | · | 1.1 | 1.1 | 1.1 | · | 1.8 | 1.4 | 1.1 | · | 1.2 | 1.3 | 1.1 | · | |
| Quick Ratio | 0.3 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.4 | · | 1.1 | 0.7 | 0.5 | · | 0.5 | 0.6 | 0.4 | · | |
| Debt / Equity | 0.6 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | |
| LT Debt / Equity | 0.6 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 5.9 | 4.0 | · | 4.6 | 5.3 | 5.7 | · |
Eficiência
| Métrica | Tendência | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | |
| Inventory Turnover | 0.7 | 0.7 | 0.7 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | |
| Receivables Turnover | 1.9 | 1.8 | 2.0 | · | 2.0 | 1.9 | 2.1 | · | 2.0 | 2.0 | 2.1 | · | 2.1 | 2.0 | 2.1 | · |
Por Ação
| Métrica | Tendência | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $18.11 | $16.80 | $18.37 | · | $19.18 | $18.32 | $17.80 | · | $17.19 | $17.38 | $16.15 | · | $16.94 | $16.88 | $16.07 | · | |
| Cash Flow / Share | · | · | $2.30 | · | · | · | $2.39 | · | · | · | $2.93 | · | · | · | $1.40 | · | |
| Dividend / Share | $1.05 | $1.05 | $1.05 | · | $1.04 | $1.04 | $1.04 | · | $0.95 | $0.95 | $0.95 | · | $0.91 | $0.91 | $0.91 | · | |
| EPS (TTM) | $3.31 | $3.94 | $6.12 | · | $5.48 | $5.16 | $5.94 | · | $4.84 | $4.52 | $4.20 | · | $5.51 | $5.33 | $5.30 | · |
Avaliação (TTM)
| Métrica | Tendência | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $20.84B | $20.58B | $20.35B | · | $19.81B | $20.07B | $20.64B | · | $19.83B | $19.72B | $19.49B | · | $19.05B | $18.81B | $18.74B | · | |
| Net Income TTM | $941M | $1.14B | $1.76B | · | $1.58B | $1.50B | $1.73B | · | $1.41B | $1.33B | $1.26B | · | $1.66B | $1.62B | $1.61B | · | |
| P/E | 45.7 | 39.9 | 24.9 | · | 24.7 | 34.9 | 30.0 | · | 38.0 | 43.0 | 45.6 | · | 37.7 | 36.5 | 37.7 | · | |
| Earnings Yield | 2.2% | 2.5% | 4.0% | · | 4.0% | 2.9% | 3.3% | · | 2.6% | 2.3% | 2.2% | · | 2.6% | 2.7% | 2.6% | · | |
| Payout Ratio | · | · | 78.3% | · | · | · | 99.7% | · | · | · | 97.9% | · | · | · | 55.2% | · | |
| Annual Payout | $1.17B | $1.19B | $1.19B | · | $1.17B | $1.15B | $1.13B | · | $1.09B | $1.10B | $1.11B | · | $1.12B | $1.10B | $1.09B | · |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Receita | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B |
| Margem Operacional % | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% |
| Lucro líquido | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B |
| EPS Diluído | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 |
| Métrica | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 |
| Índice de liquidez corrente | 1.1 | 1.2 | 1.3 | 1.0 | 1.3 |
| Índice de Liquidez Seca | 0.4 | 0.5 | 0.6 | 0.4 | 0.7 |
| Métrica | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $2.67B | $3.12B | $2.12B | $1.50B | $3.42B |
Investidores institucionais (13F) 1.552 declarantes · $46.7B total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 127 (-30 vs trimestre anterior) | 141 (-45 vs trimestre anterior) | 547 (-18 vs trimestre anterior) | 547 (+12 vs trimestre anterior) | +9.8M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| VANGUARD GROUP INC | $7.118.281.692 | 36.678.939 | 15,23% | Ações |
| BlackRock, Inc. | $3.721.532.551 | 24.592.166 | 7,96% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.722.098.919 | 17.987.834 | 5,83% | Ações |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $2.483.123.897 | 8.650.967 | 5,31% | Ações |
| STATE STREET CORP | $2.269.959.685 | 15.000.064 | 4,86% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.266.036.001 | 14.974.136 | 4,85% | Ações |
| First Eagle Investment Management, LLC | $2.090.674.677 | 13.815.335 | 4,47% | Ações |
| Invesco Ltd. | $1.346.608.236 | 8.898.488 | 2,88% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $1.228.361.034 | 8.141.586 | 2,63% | Ações |
| FRANKLIN RESOURCES INC | $1.061.064.151 | 7.011.592 | 2,27% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $962.154.023 | 6.357.986 | 2,06% | Ações |
| GREENHAVEN ASSOCIATES INC | $859.812.872 | 5.681.708 | 1,84% | Ações |
| NORGES BANK | $630.973.916 | 4.169.523 | 1,35% | Ações |
| AMERICAN CENTURY COMPANIES INC | $556.370.023 | 3.676.534 | 1,19% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $515.287.516 | 3.398.203 | 1,10% | Ações |
| MORGAN STANLEY | $502.353.875 | 3.319.590 | 1,08% | Ações |
| Clearbridge Investments, LLC | $489.222.504 | 3.232.819 | 1,05% | Ações |
| BANK OF AMERICA CORP /DE/ | $474.992.547 | 3.138.786 | 1,02% | Ações |
| JPMORGAN CHASE & CO | $440.071.112 | 2.835.692 | 0,94% | Ações |
| NORTHERN TRUST CORP | $397.274.543 | 2.625.220 | 0,85% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $385.001.377 | 2.544.118 | 0,82% | Ações |
| HARRIS ASSOCIATES L P | $355.771.231 | 2.350.963 | 0,76% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $324.096.377 | 2.141.003 | 0,69% | Ações |
| First Pacific Advisors, LP | $319.426.456 | 2.110.794 | 0,68% | Ações |
| Legal & General Group Plc | $318.049.508 | 2.101.695 | 0,68% | Ações |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $296.900.554 | 1.888.320 | 0,64% | Ações |
| Amundi | $274.921.665 | 1.816.703 | 0,59% | Ações |
| GOLDMAN SACHS GROUP INC | $266.177.531 | 1.758.921 | 0,57% | Ações |
| Longview Partners (Guernsey) LTD | $255.761.774 | 1.690.093 | 0,55% | Ações |
| BRANDES INVESTMENT PARTNERS, LP | $252.955.949 | 1.671.540 | 0,54% | Ações |
| Bank of New York Mellon Corp | $247.371.528 | 1.634.649 | 0,53% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $234.270.795 | 1.548.079 | 0,50% | Ações |
| MACKENZIE FINANCIAL CORP | $216.917.330 | 1.433.406 | 0,46% | Ações |
| Veritas Asset Management LLP | $210.852.478 | 1.393.329 | 0,45% | Ações |
| DEUTSCHE BANK AG\ | $204.226.494 | 1.349.544 | 0,44% | Ações |
| BARCLAYS PLC | $191.750.849 | 1.267.104 | 0,41% | Ações |
| UBS Group AG | $183.686.019 | 1.213.811 | 0,39% | Ações |
| WELLS FARGO & COMPANY/MN | $183.226.555 | 1.210.775 | 0,39% | Ações |
| JARISLOWSKY, FRASER Ltd | $175.028.282 | 935.130 | 0,37% | Ações |
| COOKE & BIELER LP | $171.990.480 | 1.136.526 | 0,37% | Ações |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $167.650.789 | 1.107.849 | 0,36% | Ações |
| ProShare Advisors LLC | $162.283.113 | 1.072.379 | 0,35% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $156.784.054 | 1.036.041 | 0,34% | Ações |
| RAYMOND JAMES FINANCIAL INC | $152.018.930 | 1.004.552 | 0,33% | Ações |
| Focus Partners Wealth | $144.422.511 | 954.318 | 0,31% | Ações |
| Findlay Park Partners LLP | $143.945.096 | 951.200 | 0,31% | Ações |
| M&G PLC | $134.044.663 | 887.713 | 0,29% | Ações |
| FIDUCIARY MANAGEMENT INC /WI/ | $125.873.419 | 831.781 | 0,27% | Ações |
| Cullen Capital Management, LLC | $124.804.866 | 824.720 | 0,27% | Ações |
| Swiss National Bank | $121.639.357 | 803.802 | 0,26% | Ações |
Ativistas e proprietários de 5%+ 5 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Pessoa de relato não divulgada | 8 de Setembro de 2006 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 1 de Setembro de 2006 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 25 de Agosto de 2006 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 16 de Agosto de 2006 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada | 14 de Agosto de 2006 | · | Declaração inicial | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 83 insiders · 47 diretores · 27 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Thomas E Polen Jr | Chairman, CEO and President | 13 de Agosto de 2026 M | 110.163 | 0 | 2 | $-1.172.631 |
| Vitor Roque | EVP & Chief Financial Officer | 2 de Setembro de 2026 F | 8.041 | 0 | 0 | $0 |
| Christopher Delorefice | EVP & Chief Financial Officer | 26 de Novembro de 2025 F | 22.982 | 0 | 0 | $0 |
| Christopher R Reidy | CFO and EVP of Administration | 26 de Novembro de 2021 A | 31.524 | 0 | 0 | $0 |
| David V Elkins | Executive VP and CFO | 9 de Novembro de 2012 D | 0 | 0 | 0 | $0 |
| Michael Feld | EVP, Chief Revenue Officer | 28 de Setembro de 2026 S | 19.644 | 0 | 12 | $-170.822 |
| Roland Goette | EVP and President, EMEA | 11 de Agosto de 2026 S | 14.856 | 0 | 1 | $-440.888 |
| Bilal Muhsin | EVP & President Connected Care | 2 de Julho de 2026 F | 41.359 | 0 | 0 | $0 |
| Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 24 de Junho de 2026 S | 13.172 | 0 | 5 | $-784.162 |
| Peter Menziuso | EVP and President, BDI | 1 de Junho de 2026 A | 14.258 | 0 | 0 | $0 |
| Shana Carol Neal | EVP and Chief People Officer | 6 de Abril de 2026 F | 23.966 | 0 | 0 | $0 |
| Lanesha Minnix | EVP and General Counsel | 16 de Março de 2026 A | 7.492 | 0 | 0 | $0 |
| Pamela L. Spikner | SVP Controller & CAO | 2 de Março de 2026 A | 3.323 | 0 | 0 | $0 |
| David Shan | EVP and Chief ISC Officer | 3 de Janeiro de 2026 F | 8.926 | 0 | 0 | $0 |
| Richard Byrd | EVP & President Interventional | 26 de Novembro de 2025 F | 13.849 | 0 | 0 | $0 |
| Pavan Kumar Mocherla | EVP & President, Greater Asia | 26 de Novembro de 2025 A | 5.763 | 0 | 0 | $0 |
| Michelle Quinn | EVP and General Counsel | 26 de Novembro de 2024 A | 6.927 | 0 | 0 | $0 |
| Antoine C Ezell | EVP, President Americas & CMO | 26 de Novembro de 2024 A | 11.970 | 0 | 0 | $0 |
| Thomas J Spoerel | SVPController & Chief Acct Off | 1 de Julho de 2024 F | 1.928 | 0 | 0 | $0 |
| David Hickey | EVP & President, Life Sciences | 26 de Novembro de 2023 A | 5.862 | 0 | 0 | $0 |
| Samrat S. Khichi | EVP and General Counsel | 21 de Dezembro de 2022 G | 9.251 | 0 | 0 | $0 |
| Rishi Grover | EVP and Chief ISC Officer | 8 de Julho de 2022 A | 9.439 | 0 | 0 | $0 |
| James Lim | Executive Vice President | 17 de Junho de 2022 A | 23.941 | 0 | 0 | $0 |
| Betty D Larson | EVP HR & CHRO | 25 de Fevereiro de 2022 M | 5.872 | 0 | 0 | $0 |
| Simon D Campion | EVP and Segment President | 11 de Fevereiro de 2022 G | 10.319 | 0 | 0 | $0 |
| Alexandre Conroy | EVP of Integrated Supply Chain | 3 de Fevereiro de 2022 M | 21.260 | 0 | 0 | $0 |
| Ribo Alberto Mas | EVP and Pres, Life Sciences | 26 de Novembro de 2021 A | 11.662 | 0 | 0 | $0 |
| Vincent A Forlenza | Chairman of the Board | 15 de Dezembro de 2020 G | 194.048 | 0 | 0 | $0 |
| Patrick Kaltenbach | EVP & Pres Life Sciences | 26 de Novembro de 2020 A | 10.340 | 0 | 0 | $0 |
| Charles R Bodner | SVP Corp Fin Chief Acct Office | 6 de Setembro de 2019 M | 2.037 | 0 | 0 | $0 |
| James W Borzi | EVP & Chief Supply Chain Offcr | 30 de Novembro de 2018 M | 2.775 | 0 | 0 | $0 |
| William A Tozzi | EVP Pres Interventional | 2 de Julho de 2018 A | 12.830 | 0 | 0 | $0 |
| Nabil Shabshab | Executive Vice President | 11 de Maio de 2018 M | 7.811 | 0 | 0 | $0 |
| John E Gallagher | VP, Corp Finance and Treasurer | 2 de Março de 2018 F | 1.975 | 0 | 0 | $0 |
| Linda M Tharby | Executive Vice President | 1 de Fevereiro de 2018 M | 13.437 | 0 | 0 | $0 |
| John P Groetelaars | EVP | 2 de Janeiro de 2018 A | 42.508 | 0 | 0 | $0 |
| Ellen R Strahlman | Senior Vice President | 25 de Novembro de 2017 F | 6.898 | 0 | 0 | $0 |
| Gary M Cohen | Executive Vice President | 11 de Setembro de 2017 M | 71.770 | 0 | 0 | $0 |
| Stephen Sichak | Executive Vice President | 8 de Setembro de 2017 M | 7.953 | 0 | 0 | $0 |
| Jeffrey S Sherman | Sr. VP and General Counsel | 25 de Maio de 2017 M | 22.094 | 0 | 0 | $0 |
| Jerome V Hurwitz | Executive Vice President | 6 de Maio de 2016 S | 3.027 | 0 | 0 | $0 |
| William A Kozy | Executive Vice President | 9 de Dezembro de 2015 S | 68.823 | 0 | 0 | $0 |
| Joseph Mercurio | VP and Corporate Controller | 25 de Novembro de 2014 A | 1.932 | 0 | 0 | $0 |
| Donna M Boles | Senior VP - Human Resources | 17 de Maio de 2013 M | 14.607 | 0 | 0 | $0 |
| Suketu Upadhyay | Senior VP and Controller | 20 de Novembro de 2012 A | 3.525 | 0 | 0 | $0 |
| William E. Rhodes | Senior Vice President | 20 de Novembro de 2012 A | 5.972 | 0 | 0 | $0 |
| Edward J Ludwig | Chairman | 20 de Março de 2012 G | 95.188 | 0 | 0 | $0 |
| Carrie L Byington | Conselheiro | 6 de Agosto de 2026 A | 5.018 | 0 | 0 | $0 |
| Robert Luther Huffines | Conselheiro | 6 de Agosto de 2026 A | 1.279 | 0 | 0 | $0 |
| Bertram L Scott | Conselheiro | 18 de Fevereiro de 2026 S | 36.763 | 0 | 2 | $-212.345 |
| Christopher Ian Montague Jones | Conselheiro | 4 de Fevereiro de 2026 A | 24.304 | 0 | 0 | $0 |
| Joanne Waldstreicher | Conselheiro | 27 de Janeiro de 2026 A | 3.391 | 0 | 0 | $0 |
| Jacqueline Wright | Conselheiro | 27 de Janeiro de 2026 A | 1.279 | 0 | 0 | $0 |
| William M Brown | Conselheiro | 27 de Janeiro de 2026 A | 4.663 | 0 | 0 | $0 |
| Jeffrey William Henderson | Conselheiro | 27 de Janeiro de 2026 A | 9.143 | 0 | 0 | $0 |
| Gregory Hayes | Conselheiro | 27 de Janeiro de 2026 A | 7.159 | 0 | 0 | $0 |
| Andrew R Eckert | Conselheiro | 27 de Janeiro de 2026 A | 10.423 | 0 | 0 | $0 |
| Timothy M Ring | Conselheiro | 27 de Janeiro de 2026 A | 59.160 | 0 | 0 | $0 |
| Catherine M Burzik | Conselheiro | 28 de Janeiro de 2025 A | 14.264 | 0 | 0 | $0 |
| LARSEN MARSHALL O | Conselheiro | 24 de Janeiro de 2023 A | 28.919 | 0 | 0 | $0 |
| Claire Pomeroy | Conselheiro | 25 de Janeiro de 2022 A | 9.982 | 0 | 0 | $0 |
| David F Melcher | Conselheiro | 25 de Janeiro de 2022 A | 6.180 | 0 | 0 | $0 |
| Rebecca W Rimel | Conselheiro | 8 de Setembro de 2021 S | 10.618 | 0 | 0 | $0 |
| Gary A Mecklenburg | Conselheiro | 6 de Novembro de 2018 A | 25.453 | 0 | 0 | $0 |
| Wilard J Overlock JR | Conselheiro | 6 de Novembro de 2018 A | 19.442 | 0 | 0 | $0 |
| James F Orr | Conselheiro | 24 de Janeiro de 2017 A | 24.257 | 0 | 0 | $0 |
| Basil Anderson | Conselheiro | 26 de Janeiro de 2016 A | 22.596 | 0 | 0 | $0 |
| Henry P Becton JR | Conselheiro | 3 de Novembro de 2015 A | 112.683 | 0 | 0 | $0 |
| Edward Degraan | Conselheiro | 27 de Janeiro de 2015 A | 22.416 | 0 | 0 | $0 |
| Alfred Sommer | Conselheiro | 28 de Janeiro de 2014 A | 20.689 | 0 | 0 | $0 |
| Adel Mahmoud | Conselheiro | 29 de Janeiro de 2013 A | 13.746 | 0 | 0 | $0 |
| Claire Fraser | · | 10 de Setembro de 2025 S | 22.226 | 0 | 0 | $0 |
| David T Durack | · | 28 de Abril de 2011 M | 8.908 | 0 | 0 | $0 |
| Cathy E. Minehan | · | 1 de Fevereiro de 2011 A | 8.535 | 0 | 0 | $0 |
| Scott P Bruder | · | 23 de Novembro de 2010 A | 7.626 | 0 | 0 | $0 |
| Patricia B Shrader | · | 23 de Novembro de 2010 A | 11.250 | 0 | 0 | $0 |
| John R Considine | · | 24 de Novembro de 2009 A | 93.438 | 0 | 0 | $0 |
| Alfred John Hanson | · | 25 de Novembro de 2008 A | 46.146 | 0 | 0 | $0 |
| James E Perrella | · | 31 de Outubro de 2007 A | 18.520 | 0 | 0 | $0 |
| Margeretha Af Ugglas | · | 31 de Janeiro de 2007 A | 15.920 | 0 | 0 | $0 |
| Jean Marc Dageville | · | 8 de Dezembro de 2004 M | 4.658 | 0 | 0 | $0 |
| Harry N Beaty | · | 3 de Maio de 2004 M | 9.204 | 0 | 0 | $0 |
| OLSON FRANK ALBERT | · | 11 de Fevereiro de 2004 A | 21.200 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 145 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IHI · iShares Trust | 5,24% | 943.719 SH | 11 de Setembro de 2026 | Diário |
| CZA · Invesco Exchange-Traded Fund Trust | 2,46% | 27.873 SH | 2 de Outubro de 2026 | Diário |
| EQTY · Valued Advisers Trust | 2,14% | 184.537 NS | 31 de Julho de 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 1,98% | 12.776 SH | 2 de Outubro de 2026 | Diário |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,64% | 80.100 SH | 2 de Outubro de 2026 | Diário |
| EPOL · iShares Trust | 1,60% | 69.343 SH | 11 de Setembro de 2026 | Diário |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,49% | 94.088 NS | 31 de Julho de 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1,49% | 317.073 NS | 31 de Julho de 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1,01% | 1.134.820 NS | 31 de Julho de 2026 | N-PORT |
| IYH · iShares Trust | 0,81% | 166.236 SH | 11 de Setembro de 2026 | Diário |
| RGEF · Tidal Trust III | 0,73% | 35.725 NS | 31 de Julho de 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,72% | 1.769.988 SH | 19 de Agosto de 2026 | Diário |
| FHLC · FIDELITY COVINGTON TRUST | 0,68% | 135.578 NS | 31 de Julho de 2026 | N-PORT |
| IMCV · iShares Trust | 0,68% | 44.851 SH | 11 de Setembro de 2026 | Diário |
| REVS · Columbia ETF Trust I | 0,65% | 13.100 NS | 31 de Julho de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,64% | 856.811 SH | 19 de Agosto de 2026 | Diário |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,62% | 6.797 NS | 31 de Julho de 2026 | N-PORT |
| IXJ · iShares Trust | 0,62% | 144.713 SH | 11 de Setembro de 2026 | Diário |
| CURE · Direxion Shares ETF Trust | 0,52% | 5.422 NS | 31 de Julho de 2026 | N-PORT |
| IWS · iShares Trust | 0,49% | 424.696 SH | 11 de Setembro de 2026 | Diário |
| EQIN · Columbia ETF Trust I | 0,48% | 8.836 NS | 31 de Julho de 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,42% | 148.656 NS | 31 de Julho de 2026 | N-PORT |
| FDLO · FIDELITY COVINGTON TRUST | 0,41% | 35.456 NS | 31 de Julho de 2026 | N-PORT |
| DIVB · iShares Trust | 0,40% | 46.677 SH | 11 de Setembro de 2026 | Diário |
| VO · VANGUARD INDEX FUNDS | 0,40% | 5.971.067 SH | 19 de Agosto de 2026 | Diário |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,40% | 18.133.000 | 2 de Outubro de 2026 | Diário |
| HUSV · First Trust Exchange-Traded Fund III | 0,38% | 1.706 NS | 31 de Julho de 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,38% | 31.777 NS | 31 de Julho de 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0,37% | 10.309 SH | 19 de Agosto de 2026 | Diário |
| IWR · iShares Trust | 0,37% | 1.164.966 SH | 11 de Setembro de 2026 | Diário |
| VLUE · iShares Trust | 0,36% | 194.404 SH | 11 de Setembro de 2026 | Diário |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,35% | 9.750 NS | 31 de Julho de 2026 | N-PORT |
| IMCB · iShares Trust | 0,34% | 32.267 SH | 11 de Setembro de 2026 | Diário |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 9.256 NS | 31 de Julho de 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,33% | 18.654 SH | 19 de Agosto de 2026 | Diário |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,30% | 27.935 NS | 31 de Julho de 2026 | N-PORT |
| DGRO · iShares Trust | 0,29% | 717.789 SH | 11 de Setembro de 2026 | Diário |
| XOEF · iShares Trust | 0,27% | 347 SH | 11 de Setembro de 2026 | Diário |
| DFLV · Dimensional ETF Trust | 0,26% | 104.844 NS | 31 de Julho de 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 5.494 SH | 11 de Setembro de 2026 | Diário |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 1.085.457 SH | 2 de Outubro de 2026 | Diário |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,20% | 10.851 SH | 2 de Outubro de 2026 | Diário |
| EUSA · iShares, Inc. | 0,19% | 20.800 SH | 11 de Setembro de 2026 | Diário |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,19% | 1.919 NS | 31 de Julho de 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,19% | 5.597.000 | 2 de Outubro de 2026 | Diário |
| DFUV · Dimensional ETF Trust | 0,18% | 171.825 NS | 31 de Julho de 2026 | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,18% | 6.482.000 | 2 de Outubro de 2026 | Diário |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,18% | 255.000 | 1 de Outubro de 2026 | Diário |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,18% | 1.556.657 SH | 19 de Agosto de 2026 | Diário |
| VYM · VANGUARD WHITEHALL FUNDS | 0,18% | 1.134.690 SH | 19 de Agosto de 2026 | Diário |
| PFM · Invesco Exchange-Traded Fund Trust | 0,18% | 7.746 SH | 2 de Outubro de 2026 | Diário |
| FEUS · FlexShares Trust | 0,17% | 1.155 NS | 31 de Julho de 2026 | N-PORT |
| IVE · iShares Trust | 0,16% | 457.195 SH | 11 de Setembro de 2026 | Diário |
| VTV · VANGUARD INDEX FUNDS | 0,16% | 2.617.912 SH | 19 de Agosto de 2026 | Diário |
| IUSV · iShares Trust | 0,15% | 240.462 SH | 11 de Setembro de 2026 | Diário |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,15% | 4.447.000 | 2 de Outubro de 2026 | Diário |
| ILCV · iShares Trust | 0,14% | 10.712 SH | 11 de Setembro de 2026 | Diário |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,14% | 63.464 SH | 19 de Agosto de 2026 | Diário |
| EMGF · iShares, Inc. | 0,14% | 14.306 SH | 10 de Setembro de 2026 | Diário |
| DSI · iShares Trust | 0,14% | 42.114 SH | 11 de Setembro de 2026 | Diário |
| IWD · iShares Trust | 0,14% | 632.304 SH | 11 de Setembro de 2026 | Diário |
| PRF · Invesco Exchange-Traded Fund Trust | 0,12% | 68.767 SH | 2 de Outubro de 2026 | Diário |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,12% | 171.632 SH | 19 de Agosto de 2026 | Diário |
| GLBL · Pacer Funds Trust | 0,12% | 8 NS | 31 de Julho de 2026 | N-PORT |
| DFVX · Dimensional ETF Trust | 0,12% | 3.749 NS | 31 de Julho de 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,11% | 57.721 SH | 2 de Outubro de 2026 | Diário |
| ESG · FlexShares Trust | 0,11% | 840 NS | 31 de Julho de 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,10% | 9.358 SH | 2 de Outubro de 2026 | Diário |
| HDUS · Lattice Strategies Trust | 0,10% | 1.192 NS | 31 de Julho de 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 4.285 SH | 2 de Outubro de 2026 | Diário |
| TOPC · iShares Trust | 0,09% | 171 SH | 11 de Setembro de 2026 | Diário |
| ACVF · ETF Opportunities Trust | 0,09% | 795 NS | 31 de Julho de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,08% | 244.485 NS | 31 de Julho de 2026 | N-PORT |
| XVV · iShares Trust | 0,08% | 3.163 SH | 11 de Setembro de 2026 | Diário |
| PBP · Invesco Exchange-Traded Fund Trust | 0,07% | 1.621 SH | 2 de Outubro de 2026 | Diário |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,07% | 47.745 SH | 2 de Outubro de 2026 | Diário |
| IVV · iShares Trust | 0,07% | 3.473.127 SH | 11 de Setembro de 2026 | Diário |
| CRBN · iShares Trust | 0,07% | 4.897 SH | 11 de Setembro de 2026 | Diário |
| ILCB · iShares Trust | 0,07% | 5.340 SH | 11 de Setembro de 2026 | Diário |
| BKLC · BNY Mellon ETF Trust | 0,07% | 24.016 NS | 31 de Julho de 2026 | N-PORT |
| IWB · iShares Trust | 0,07% | 197.581 SH | 11 de Setembro de 2026 | Diário |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,07% | 38.024 NS | 31 de Julho de 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0,07% | 13.955 NS | 31 de Julho de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,07% | 53.117 NS | 31 de Julho de 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,07% | 4.662 NS | 31 de Julho de 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0,07% | 321.801 SH | 19 de Agosto de 2026 | Diário |
| ESGV · VANGUARD WORLD FUND | 0,07% | 64.270 SH | 19 de Agosto de 2026 | Diário |
| TOV · EA Series Trust | 0,07% | 1.117 NS | 31 de Julho de 2026 | N-PORT |
| IYY · iShares Trust | 0,07% | 11.794 SH | 11 de Setembro de 2026 | Diário |
| DXUV · Dimensional ETF Trust | 0,07% | 2.283 NS | 31 de Julho de 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0,07% | 24 NS | 31 de Julho de 2026 | N-PORT |
| IWV · iShares Trust | 0,07% | 78.106 SH | 11 de Setembro de 2026 | Diário |
| USCL · iShares Trust | 0,07% | 10.939 SH | 11 de Setembro de 2026 | Diário |
| ITOT · iShares Trust | 0,07% | 359.241 SH | 11 de Setembro de 2026 | Diário |
| DFUS · Dimensional ETF Trust | 0,07% | 83.341 NS | 31 de Julho de 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,07% | 1.039 NS | 31 de Julho de 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,06% | 6.630 NS | 31 de Julho de 2026 | N-PORT |
| LRGF · iShares Trust | 0,06% | 13.430 SH | 11 de Setembro de 2026 | Diário |
| PHDG · Invesco Actively Managed Exchange-T… | 0,06% | 215 SH | 2 de Outubro de 2026 | Diário |
| VOO · VANGUARD INDEX FUNDS | 0,06% | 7.153.108 SH | 19 de Agosto de 2026 | Diário |
| VTI · VANGUARD INDEX FUNDS | 0,06% | 8.748.767 SH | 19 de Agosto de 2026 | Diário |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,06% | 47.858 SH | 19 de Agosto de 2026 | Diário |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,06% | 47.190 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,06% | 23.933 SH | 19 de Agosto de 2026 | Diário |
| TOK · iShares Trust | 0,06% | 795 SH | 11 de Setembro de 2026 | Diário |
| DCOR · Dimensional ETF Trust | 0,06% | 11.787 NS | 31 de Julho de 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,06% | 1.923 NS | 31 de Julho de 2026 | N-PORT |
| URTH · iShares, Inc. | 0,06% | 25.569 SH | 11 de Setembro de 2026 | Diário |
| JFLI · J.P. Morgan Exchange-Traded Fund Tr… | 0,05% | 156 NS | 31 de Julho de 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,05% | 21.539 NS | 31 de Julho de 2026 | N-PORT |
| TILT · FlexShares Trust | 0,05% | 6.952 NS | 31 de Julho de 2026 | N-PORT |
| LDEM · iShares Trust | 0,05% | 91 SH | 11 de Setembro de 2026 | Diário |
| ACWI · iShares Trust | 0,05% | 94.438 SH | 11 de Setembro de 2026 | Diário |
| DFSU · Dimensional ETF Trust | 0,05% | 6.917 NS | 31 de Julho de 2026 | N-PORT |
| EMXF · iShares Trust | 0,04% | 384 SH | 11 de Setembro de 2026 | Diário |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,04% | 11.545 SH | 2 de Outubro de 2026 | Diário |
| ROUS · Lattice Strategies Trust | 0,04% | 1.753 NS | 31 de Julho de 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 247.589 SH | 19 de Agosto de 2026 | Diário |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 796 SH | 2 de Outubro de 2026 | Diário |
| GLOF · iShares Trust | 0,04% | 380 SH | 11 de Setembro de 2026 | Diário |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 1.792 NS | 31 de Julho de 2026 | N-PORT |
| EMXC · iShares, Inc. | 0,02% | 33.336 SH | 11 de Setembro de 2026 | Diário |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,02% | 30.768 SH | 19 de Agosto de 2026 | Diário |
| EEM · iShares, Inc. | 0,02% | 31.606 SH | 10 de Setembro de 2026 | Diário |
| IEMG · iShares, Inc. | 0,02% | 152.904 SH | 10 de Setembro de 2026 | Diário |
| LGDX · Tidal Trust III | 0,01% | 113 NS | 31 de Julho de 2026 | N-PORT |
| VXUS · VANGUARD STAR FUNDS | 0,01% | 186.147 SH | 19 de Agosto de 2026 | Diário |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,01% | 125.091 SH | 19 de Agosto de 2026 | Diário |
| VSGX · VANGUARD WORLD FUND | 0,01% | 2.529 SH | 19 de Agosto de 2026 | Diário |
| AQLT · iShares Trust | 0,01% | 158 SH | 10 de Setembro de 2026 | Diário |
| PEVC · Pacer Funds Trust | 0,01% | 1 NS | 31 de Julho de 2026 | N-PORT |
| ACWX · iShares Trust | 0,01% | 3.911 SH | 10 de Setembro de 2026 | Diário |
| IXUS · iShares Trust | 0,01% | 18.527 SH | 11 de Setembro de 2026 | Diário |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 de Julho de 2026 | Diário |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 de Julho de 2026 | Diário |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 de Julho de 2026 | Diário |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 de Julho de 2026 | Diário |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | 15 de Julho de 2026 | Diário |
| VCEB · VANGUARD WORLD FUND | · | · | 30 de Julho de 2026 | Diário |
BDX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
Preço-alvo de 12 meses
12 analistas · 2026-10-01Alvo médio $195.67 +10,7%
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| BDX | · | 25.3 | 8.2% | 7.7% | 6.5% | · |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | · | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| GEHC | · | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | · |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.